Simplex Trading’s Cidara Therapeutics CDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-47,200
Closed -$10.4M 9141
2025
Q4
$10.4M Buy
47,200
+27,000
+134% +$4.36M 0.01% 824
2025
Q3
$1.93M Sell
20,200
-32,300
-62% -$2.06M ﹤0.01% 2360
2025
Q2
$2.56M Buy
52,500
+50,700
+2,817% +$1.22M ﹤0.01% 1890
2025
Q1
$38K Buy
+1,800
New +$40K ﹤0.01% 6041
2023
Q4
Sell
-975
Closed -$18K 8859
2023
Q3
$18K Buy
975
+90
+10% +$1.77K ﹤0.01% 6697
2023
Q2
$20K Buy
885
+460
+108% +$10.8K ﹤0.01% 6762
2023
Q1
$10K Buy
+425
New +$12.1K ﹤0.01% 7527
2022
Q2
Sell
-175
Closed -$2K 10036
2022
Q1
$2K Buy
+175
New +$2.97K ﹤0.01% 9826
2021
Q4
Sell
-30
Closed -$1K 10526
2021
Q3
$1K Hold
30
﹤0.01% 9623
2021
Q2
$1K Buy
30
+29
+2,900% +$1.23K ﹤0.01% 9800
2021
Q1
$4K Buy
+1
New +$49 ﹤0.01% 8250
2020
Q4
Sell
-2
Closed -$12K 8379
2020
Q3
$12K Sell
2
-9
-82% -$636 ﹤0.01% 6690
2020
Q2
$77K Buy
11
+8
+267% +$518 ﹤0.01% 5075
2020
Q1
$15K Buy
3
+1
+50% +$60 ﹤0.01% 6164
2019
Q4
$18K Buy
+2
New +$92 ﹤0.01% 6013
2018
Q4
Sell
-2
Closed -$14K 7053
2018
Q3
$14K Buy
+2
New +$176 ﹤0.01% 6215

Simplex Trading's CDTX Position: Q1 2026 in Review

Simplex Trading sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 5,230 shares — an estimated $1.16M sold.

Simplex Trading first reported a position in CDTX in Q1 2018 and held it in 11 quarters. The position peaked at $3.31M in Q2 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Simplex Trading reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 5,230 Cidara Therapeutics shares in Q1 2026, an estimated $1.16M.
  • Simplex Trading first reported a position in Cidara Therapeutics in Q1 2018 and held it in 11 quarters.
  • Simplex Trading's Cidara Therapeutics position peaked at $3.31M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.